[The effects of oxidative stress to PCOS].
OBJECTIVE
To investigate the correlation between oxidative stress and PCOS, to provide an evidence for the treatment of PCOS.


METHODS
The levels of maternal serum LPO, MDA, SOD, VE and VC were measured in 30 patients with PCOS (PCOS group 1) and in 30 normal women (control group) by chemicalorimetry. After being measured, the patients with PCOS (PCOS group 1) took VE 0.1 qd x 3 months, VC 0.2 bid x 3 months and Diane-35 (Ethinylestradiol and Cyproterone Acetate Tablets) 1 # qd x 21 d/month x 3 months. The LPO, MDA, SOD, VE and VC were measured after three months. The other 30 patients with PCOS (PCOS group 2) were chosen to take Diane-35 (Ethinylestradiol and Cyproterone Acetate Tablets) 1 qd x 21 d/month x 3 months only. The menstrual cycles were viewed in PCOS group 1 and PCOS group 2 for three months.


RESULTS
The levels of maternal serum LPO and MDA in patients with PCOS (PCOS group 1) were significant higher than that in normal women (control group) (P < 0.05). The levels of maternal serum VE, VC and SOD in patients with PCOS (PCOS group 1) were lower than that in normal women (control group) (P < 0.05). The levels of LPO and MDA after taking Diane-35, VE and VC were lower than that before taking Diane-35, VE and VC. The levels of VE, VC and SOD after taking Diane-35, VE and VC were higher than that before taking Diane-35, VE and VC. The recoveries of menstrual cycles in PCOS group 1 were better than that in PCOS group 2.


CONCLUSIONS
The PCOS may be related to oxidative stress (the metabolism imbalance of reactive oxygen species). The antioxidants may improve the prognosis of PCOS.
Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Dan
D
Zhang
Wan-Ying
WY
Luo
Hua
H
Liao
Cheng-Fang
CF
Wang
Ying
Y
Sun
D000726:Androgen Antagonists / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000097:blood / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy; D013482:Superoxide Dismutase / Q000097:blood; D014810:Vitamin E / Q000097:blood / Q000627:therapeutic use
D000726:Androgen Antagonists; D000975:Antioxidants; D004338:Drug Combinations; D008054:Lipid Peroxides; D014810:Vitamin E; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D008315:Malondialdehyde; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D013482:Superoxide Dismutase; D001205:Ascorbic Acid